Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).

IF 3.4 2区医学 Q1 UROLOGY & NEPHROLOGY

Sexual medicine reviews Pub Date : 2025-10-04 DOI:10.1093/sxmrev/qeaf035

Noah Stern, Petar Bajic, Jeffrey Campbell, Paolo Capogrosso, Trustin Domes, Eduardo P Miranda, John P Mulhall, Bruno Nascimento, Michael Pignanelli, Alexander W Pastuszak, Gerald Brock

{"title":"Evolving medical management of erectile dysfunction: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024).","authors":"Noah Stern, Petar Bajic, Jeffrey Campbell, Paolo Capogrosso, Trustin Domes, Eduardo P Miranda, John P Mulhall, Bruno Nascimento, Michael Pignanelli, Alexander W Pastuszak, Gerald Brock","doi":"10.1093/sxmrev/qeaf035","DOIUrl":null,"url":null,"abstract":"Introduction: Treatment of erectile dysfunction is based on pharmacotherapy for most patients.Aim: To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes.Methods: A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed, and consensus statements were developed after presentation at the 2024 ICSM.Results: Eight recommendations are provided with the corresponding level of evidence and grade of recommendation.Conclusions: The management of erectile dysfunction should be personalized to address the psychosocial needs and expectations of both the patient and their partner. PDE5 inhibitors remain the first-line treatment for most men, while intracavernosal injections, vacuum erection devices, and penile prostheses serve as second-line options, with treatment decisions guided by patient preferences. Key recommendations are summarized in table 1.","PeriodicalId":21813,"journal":{"name":"Sexual medicine reviews","volume":" ","pages":"513-537"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sexual medicine reviews","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/sxmrev/qeaf035","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Treatment of erectile dysfunction is based on pharmacotherapy for most patients.

Aim: To review the current data on pharmacotherapy for erectile dysfunction based on efficacy, psychosocial outcomes, and safety outcomes.

Methods: A review of the literature was undertaken by the committee members. All related articles were critically analyzed and discussed, and consensus statements were developed after presentation at the 2024 ICSM.

Results: Eight recommendations are provided with the corresponding level of evidence and grade of recommendation.

Conclusions: The management of erectile dysfunction should be personalized to address the psychosocial needs and expectations of both the patient and their partner. PDE5 inhibitors remain the first-line treatment for most men, while intracavernosal injections, vacuum erection devices, and penile prostheses serve as second-line options, with treatment decisions guided by patient preferences. Key recommendations are summarized in table 1.

查看原文本刊更多论文

勃起功能障碍的不断发展的医学管理：来自第五届性医学国际咨询会议（ICSM 2024）的建议。

简介：大多数患者的勃起功能障碍的治疗是基于药物治疗。目的：回顾目前关于勃起功能障碍药物治疗的有效性、社会心理结局和安全性结局的数据。方法：由委员会成员进行文献回顾。所有相关文章都进行了批判性分析和讨论，并在2024年ICSM上发表后形成了共识声明。结果：8条建议均具有相应的证据水平和推荐等级。结论：勃起功能障碍的治疗应个性化，以满足患者及其伴侣的社会心理需求和期望。PDE5抑制剂仍然是大多数男性的一线治疗，而海绵体内注射、真空勃起装置和阴茎假体作为二线治疗选择，治疗决定取决于患者的偏好。表1总结了主要建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Sexual medicine reviews UROLOGY & NEPHROLOGY-

CiteScore

7.60

自引率

8.30%

发文量